Seebri Breezhaler (glycopyrronium bromide) Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Nxera Pharma

2013-001445-13: Assessment of the early bronchodilation of Glycopyrronium bromide compared to Tiotropium in patients with moderate to severe COPD

Not yet recruiting

150

Europe

Glycopyrronium bromide, Spiriva Handihaler, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler, Spiriva Handihaler

Novartis Pharma GmbH, Novartis Pharma GmbH

Chronic Obstructive Pulmonary Disease (COPD), COPD is a chronic condition of the lungs which causes people to suffer symptoms such as shortness of breath and coughing., Diseases [C] - Respiratory Tract Diseases [C08]

2021-004972-32: Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children (6 to less than 12 years) with asthma. Farmacocinética, farmacodinámica, seguridad y tolerabilidad de bromuro de glicopirronio en niños con asma (de 6 a menos de 12 años de edad).

Ongoing

Europe, RoW

Glycopyrronium bromide 25 μg of active moiety in the capsule, Glycopyrronium bromide 12.5 μg of active moiety in the capsule, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler

Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG

Asthma Asma, Asthma Asma, Diseases [C] - Respiratory Tract Diseases [C08]

NCT05222529 / 2021-004972-32: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Recruiting

Europe, RoW

Glycopyrronium bromide 25ug, NVA237, Placebo, Glycopyrronium bromide 12.5ug

Novartis Pharmaceuticals, Novartis Pharma AG

Asthma

06/25



	Diseases Companies Products Productz Mechanisms of Action Sites